The Central Social Insurance Medical Council, a key Japanese reimbursement policy panel better known as Chuikyo, approved an outline of…
REGULATORY
Patient Groups Push Back against Delisting OTC-Like Drugs; Panel Leans Toward Higher Copays
Japan’s national health insurance panel signaled on November 20 that removing “OTC-like” prescription drugs from coverage would be difficult, after patient organizations unanimously warned against delisting the medicines. While rejecting full exclusion, several groups indicated they could accept higher copayments…
To read the full story
Related Article
- MHLW Names 77 Active Ingredients for OTC-Like Drug Charges
December 26, 2025
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel Backs Extra Charges for OTC-Like Drugs While Keeping Coverage, but Design Details Still Divisive
November 28, 2025
- Govt Weighs Additional Copays for OTC-Like Drugs in Economic Package
November 19, 2025
- Chuikyo Split over Higher Copays under LLP Scheme; Payer Push Meets Provider Caution
November 17, 2025
- MHLW Weighs Higher Copay Ratios for LLPs; 1/2 to Full Gap on the Table
November 7, 2025
- MHLW Outlines 4 Key Themes for 2026 Reform, Eyes OTC-Like Meds, CEA for Efficiency
October 24, 2025
- MHLW Panel Launches Full Debate on Drug Coverage Reform; LLPs, Biologics, OTC-Like Meds in Focus
October 17, 2025
- Panel Split on Delisting OTC-Like Drugs from Insurance Coverage
October 3, 2025
- Panel Flags Concern over Drug-Only Focus in Proposed Cost-Cuts for 2026 Reform
September 29, 2025
REGULATORY
- MHLW Orders Label Revisions for Aspirin, CAR-T Therapies, and Other Drugs
January 14, 2026
- Japan to Stick with 7 New Drug Approval Rounds a Year
January 14, 2026
- MHLW to Set Up Expert Panel on Using Disease Registries in Drug Development
January 13, 2026
- Chuikyo Moves to Allow Special Mixed-Billing for Santen’s Myopia Drug
January 13, 2026
- Japan Panel to Review AbbVie’s Aquipta, Ipsen’s Sohonos on January 23
January 13, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…